Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2022; 43(01): 040-046
DOI: 10.1055/s-0042-1742400
Review Article

Is Low-Dose Abiraterone for Prostate Cancer An Attractive Strategy for Limited Resource Settings?

Treshita Dey
1   Department of Radiotherapy and Oncology, Post Graduate Institute of Medical Education and Research, Chandigarh, India
,
Shikha Goyal
1   Department of Radiotherapy and Oncology, Post Graduate Institute of Medical Education and Research, Chandigarh, India
,
Kannan Periasamy
1   Department of Radiotherapy and Oncology, Post Graduate Institute of Medical Education and Research, Chandigarh, India
,
Renu Madan
1   Department of Radiotherapy and Oncology, Post Graduate Institute of Medical Education and Research, Chandigarh, India
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints
Zoom Image

Abstract

Abiraterone acetate in combination with prednisone is approved for locally advanced as well as metastatic (hormone-sensitive and castrate-resistant) prostate cancer, with overall or disease-free survival gains in suitable patients. Long-term use poses a significant financial strain on the self-paying patients as well as the national health insurance schemes. Abiraterone is known to be a drug with a high “food effect” with increased bioavailability following high fat diet. Some retrospective series and phase 1 and 2 clinical studies have explored the use of low-dose abiraterone (at 25% of standard dose) with high fat meal with similar bioavailability and biochemical response to the standard drug dose. We review and report the available literature for this approach and discuss the financial and scientific implications of the same.

Keywords

prostate cancer - abiraterone acetate - low dose abiraterone - pharmacokinetics - PSA response

Authors' Contribution

T.D. contributed toward Concept, design, definition of intellectual content, literature search, data acquisition, data analysis, statistical analysis, manuscript preparation, and manuscript review. S.G. worked toward concept, design, definition of intellectual content, literature search, clinical studies, data acquisition, data analysis, statistical analysis, manuscript preparation, manuscript editing, and manuscript review. K.P. defined intellectual content and did data acquisition and manuscript review. R.M. contributed toward concept, design, literature search, data acquisition, data analysis, manuscript editing, and manuscript review.


Sources of Support

None.




Publication History

Article published online:
15 February 2022

© 2022. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India